A novel synthetic methodology for preparing amide conjugates of the DO3A-N-(-amino)propionate chelator is described, using the synthesis of the DO3A-N-(-benzoylamido)propionate chelator as an illustrative example. The model Gd(DO3A-N-(-benzoylamido)propionate) chelate displays accelerated water exchange, stability in a wide pH range and inertness towards transmetallation by Zn 2+ . The Gd(DO3A-N-(-benzoylamido)propionate) complex is mainly excreted via the kidneys, producing a significant increase of the kidney medulla/cortex enhancement ratio in MR images of Wistar rats, reflecting probably its increased hydrophobicity compared to Gd(DTPA).
Introduction
Since its introduction around 30 years ago, MRI has evolved into the leading imaging modality both in the clinics and in biomedical sciences (1) . Incremental developments in instrumentation, particularly the use of increasingly higher magnetic fields, and the use of contrast agents (CAs), have driven MRI to the forefront of medical imaging (2) . Gd 3+ chelates are the most useful CAs for MRI due to the high paramagnetism (7 unpaired electrons) and long electronic relaxation times of the Gd 3+ ion (3) . To ensure safety, Gd 3+ ions are used as complexes with poly(aminocarboxylate)
ligands, which prevents the inherent toxicity of the free metal ion and modulates its unfavorable pharmacokinetic behaviour. The efficacy of a CA is measured by its relaxivity (r 1 , r 2 )-the enhancement of the relaxation rate of the water protons brought about by a 1 mM concentration of Gd 3+ (4, 5) . Increasing detection sensitivity, by maximizing relaxivity, has been the driving force in the development of new CAs (6) .
Nonetheless, the high relaxivities predicted theoretically haven't yet been achieved in spite of the tremendous efforts and developments in the field (7) . The main approaches to enhance detection sensitivity involve optimizing the relaxivity of individual chelates, clustering a high number of (high relaxivity) chelates into (bio)macromolecular carriers or self-assembly of monomeric chelates into supramolecular structures, and directing chelate constructs to the sites of interest by attaching targeting moieties recognized specifically by cellular receptors (6, 8) . All these approaches require chemical modification of the basic chelator structure in order to introduce "handles" for chemical functionalization.
A few years ago, the discovery of severe toxicity associated with repeated CA MRI in individuals suffering from kidney function impairment cast doubt about the safety of MRI CAs (9, 10) . This condition, named Nefrogenic Systemic Fibrosis (NSF), owing to generalized formation of fibrotic (scarring) plates in the skin and internal organs, was correlated with the use of Gd 3+ chelates of DTPA bis-amide chelators (11) .
Release of Gd 3+ ions in vivo, owing to insufficient kinetic and thermodynamic stability of the Gd(DTPA-bis-amide) chelates, seems the most likely reason for CA toxicity (12, 13) . Importantly, only a few cases have been associated with macrocyclic CAs of the DOTA family, all in patients suffering from kidney disease (13) (14) (15) . The much higher kinetic and thermodynamic stability of the macrocyclic DOTA-type CAs precludes release of Gd 3+ ions in vivo. The adoption of stricter guidelines concerning the use of Gd 3+ -based CA has drastically reduced the number of NSF cases reported (16 ) has become one of the CAs of choice in the clinical setting (17) . Improving the performance of DOTA-type CAs (targeting, multimerization, responsiveness, etc.)
requires chemical elaboration of the basic DOTA scaffold to allow conjugation to (bio)molecules. Endowing DOTA chelators with conjugability without compromising stability is a core problem in CA research. In fact, the most convenient route for chemical functionalization of the DOTA skeleton, differentiating an acetate arm for amide coupling, reduces the thermodynamic and kinetic inertness of Gd(DOTAmonoamide)-type chelates (18) . Furthermore, neutral Gd(DOTA-monoamide)-type chelates display much slower water exchange, limiting the relaxivities potentially achievable by chelates displaying optimized rotational correlation times ( R ).
Introducing pendant functional groups on the ethylenediamine bridges on the DOTA skeleton is an effective, although costly solution (19) . It is preferable from the synthetic point of view to elaborate the (pre-formed) available cyclen skeleton than starting chelator synthesis from scratch. We have recently reported the synthesis of a new chelator, DO3A-N-(-amino)propionate (L 2 , Scheme 1) and the relaxometric characterization of its Gd 3+ complex. The -amino substituted propionate arm presumably imposes steric compression around the water binding site on the complex, resulting in an accelerated water exchange rate k ex (20) . In the same year, Botta and coworkers reported a bifunctional chelator, DOTAMAP-En, and an amide conjugate, DOTAMAP-En-C18, bearing a propionamide arm. Even higher water exchange rates were demonstrated for the Gd(DOTAMAP-En) and for the Gd(DOTAMAP-En-C18)
chelates, presumably also owing to steric compression (21) . The k ex value for the Gd(DO3A-N-(-amino)propionate) (GdL 2 ) chelate is of the same order of magnitude as that reported for its (unsubstituted) propionate analogue Gd(DOTA-N-propionate)-in the range considered ideal for attaining high relativities at intermediate/high field (18, 20, 22) . Moreover, the GdL 2 complex is stable in the pH range 2-10 and inert towards transmetallation with Zn 2+ . The pendant available amine group is ideal for conjugation through a variety of ligation chemistries. 
Results and Discussion

Synthesis
Allying stability to conjugability is an important requisite for developing metal chelates into imaging and/or therapeutic agents. We have proposed before that the pendant amine group on the -aminopropionate arm on the DO3A-N-(-amino)propionate chelator is an ideal handle for conjugation to (bio)molecules (20) .
There are literature precedents for the direct conjugation of functionalised (pre-formed)
chelates (24) . However, solubility issues and difficult manipulations and purifications can be avoided, especially with radio-labelled metal chelates, by labelling fully deprotected conjugates. A cysteinyl conjugate of the DO3A-N-(-amino)propionate was recently described by us using the "conventional approach": amide coupling of a S,Nprotected cysteinyl block to a protected advanced intermediate followed by deprotection (23) . In this work we disclose a new expeditious strategy for the synthesis of amide conjugates of the DO3A-N-(-amino)propionate scaffold (Scheme 1). Introducing a pre-formed Boc-dehydroamide (Ph, Boc)--AlaOMe 2 into the cyclen scaffold via Michael addition is the key step in this reaction sequence. Building up on our previous experience on the synthesis of bifunctional chelator L 2 we envisaged that (Boc, amide)-dehydroalanines of type 2 could fulfil electronic and steric requirements to perform well as electrophiles in Michael addition to cyclen. (Boc, amide)-dehydroalanines of type 2 can be readily prepared in two steps from serine methyl ester hydrochloride 1 and stored at room temperature for extended periods (25) .
Michael addition of block (2) to cyclen 3 proceeded smoothly in acetonitrile, using bi-products of (carbodiimide-based) coupling reagents (23) . This approach is general, applicable to Boc-dehydroamides of type 2 lacking acid sensitive moieties/protecting groups and basic sites susceptible to alkylation on the amide moiety.
Solution NMR and relaxometric studies
As discussed above, the aim of this work is to ascertain if Gd 3+ chelates of amide conjugates of the DO3A-N-(-amino)propionate metal chelator retain the high stability, inertness and fast water exchange of its parent GdL 2 complex. The soluble, low molecular weight GdL 1 complex (Scheme 1) was selected as a model system in order to avoid solubility and self-assembly complicating issues. The Gd-water proton distance was fixed to r GdH = 3.1Å, and the distance of closest approach between the Gd 3+ ion and the outer sphere protons to Gd H = 3.6 Å (22,27).
The parameters obtained from the simultaneous fitting of the data are shown on Table 1 , and the corresponding fitted curves are shown in Figure 1 . (29, 30) , have been proposed to be the most likely mechanisms for Gd 3+ leakage (33, 34) . This can occur via the direct attack of the endogenous metal on GdL, or via proton-assisted dissociation of GdL, followed by recombination of the ligand with the attacking metal ion (35) (36) (37) . Kinetic studies carried out close to physiological pH using much higher cationic concentrations than the free concentrations expected in plasma, led to the general conclusion that the dissociation of DTPA-like linear complexes occurs mainly via direct transmetallation, while the much slower dissociation of DOTA-like macrocyclic chelates uses mainly proton-assisted pathways (35) (36) (37) .
The kinetic inertness of the GdL 1 complex was evaluated using the simple transmetallation assay developed by Muller and co-workers (38) . Complex transmetallation by Zn 2+ was studied in phosphate-buffer (10 mM, pH 7.1) (Figure 2 ).
Replacement of Gd 3+ by Zn 2+ in the initial complex generates a time-dependent decrease of the paramagnetic contribution to the water proton spin-lattice relaxation rate (R 1p ) due to precipitation of GdPO 4 .
The time evolution of the relative water proton paramagnetic relaxation rate R 1p (t)/R 1p (0) for the GdL 1 complex in phosphate buffer, in the absence and in the presence of Zn 2+ (Figure 2 ) fulfils the accepted empirical criteria for kinetic and thermodynamic stability (38) . Although the Zn 2+ concentrations used in this empirical assay are several orders of magnitude higher than its free or exchangeable concentrations in plasma (30) , the results provide a fast initial screening between inert and labile Gd 3+ complexes. Furthermore, the independence of the paramagnetic relaxation rates for the GdL 1 complex from the solution pH ( Figure 3SI ) confirms that the complex is stable in the pH range 2-11. The interaction of the GdL1 complex with human serum albumin (HSA) was studied by relaxometric titration ( Figure 4SI ). A very weak binding was detected, which is not likely to affect the pharmacokinetic behaviour of the complex in vivo.
MRI Studies
Comparative MRI studies have been performed at 7.0 Tesla in male Wistar rats with GdL 1 and Gd(DTPA). The GdL 1 contrast agent was well tolerated by the animals at the dose used. No gross side effects were observed during the injection, immediately or several days after the experiment. During experiments, rats body temperature remained stable and no alteration on the body functions was observed. Overall, GdL 1 seemed to be harmless to the animals. Nevertheless, a more detailed study would be required to further assess its toxicology. The features of the data in Figure 3 are better understood as illustrated in Figure   4 , which shows their quantitative analysis. Each time point corresponds to the average intensity within ROIs placed on the different organs. In order to compare the results for all the animals under study (n = 4), the data were normalized by calculating the mean relative enhancement of each ROI. The scattering in the time course curves of the average relative enhancement of the ROIs was caused by animal respiratory motion.
Muscle and liver enhancement is comparably low with both complexes. The relative enhancement obtained with Gd(DTPA) increased almost immediately after intravenous injection from 0 up to about 250% in the kidney medulla and 200% in the kidney cortex, followed by a steady decrease to values around 120% and 80%, respectively, after 50 minutes. The time course of the average relative enhancement after injection of Gd(DTPA) ( Figure 4A ) is in good agreement with the literature for Gd(DTPA) (39, 40) or other low molecular weight Gd-based contrast agents (41) (42) (43) (44) (45) .
The renal pharmacokinetic behavior of GdL 1 is significantly different from that observed for Gd(DTPA). Kidney cortex enhancement build-up is slower than for Gd(DTPA), reaching a maximum of about 100% after 10 minutes post injection, followed by a steady decrease to a value (~80%) comparable to that reached by Gd(DTPA) after 50 minutes. However, the main difference between GdL 1 and Gd(DTPA) regards kidney medulla enhancement. While for Gd(DTPA) there is a sharp increase just after injection, followed by a steady decrease, for the GdL 1 complex a saturation-like kinetic behaviour is observable.
After 50 minutes, a significantly higher enhancement of the kidney medulla is attained with the GdL 1 complex comparing to Gd(DTPA) (200% vs 120%). At the same dose, the GdL 1 complex resulted in a considerably lower initial signal enhancement than Gd(DTPA) at both the cortex and medulla, which is not in agreement with their in vitro relaxivities, which are comparable. As a consequence of the disparate pharmacokinetics, the ratio of medulla/cortex enhancement increases significantly for the GdL 1 complex over the duration of the experiment, while it is approximately constant for the Gd(DTPA) complex.
The pharmacokinetic behaviour in rats of the Gd(DOTA) complex regarding kidney excretion is similar to that displayed by the Gd(DTPA) complex (41): a sharp enhancement of kidney medulla and cortex after injection followed by a steady decrease with the enhancement ratio medulla/cortex approximately constant over the experiment duration. This suggests that, although charge effects (-2 for the Gd(DTPA) complex and -1 for the GdL 1 complex) cannot be ruled out, the observed difference of pharmacokinetic behaviour is likely due to the higher hydrophobicity of the GdL 1 complex comparing to the Gd(DTPA) complex.
It has been shown previously that the in vitro and in vivo relaxivities of Gdbased CAs can be significantly different, as the latter are affected by tissue structure and physiology (39, 46) . Gd(DTPA) was found to display relaxivities considerably lower in rat kidney cortex or medulla comparing to the values measured in saline solution or in other tissues. This effect is related to CA compartmentalization in the kidney (47, 48) .
The quantitative determination of the in vivo relaxivity of a CA requires knowledge of its local concentration. In some cases, CA concentration has been obtained from independent measurements. These studies, however, are not without difficulties, since they often induce significant perturbations to the tissues, by studying intact excised tissues (49), making measurements post-mortem (47), or ensuring a constant infusion of the CA in order to establish a steady state concentration (48) .
Lacking such experiments, estimation of the relative in vivo relaxivities would require to measure the effective T 1 values on different ROIs, to assume a linear dependence of signal enhancement with the local CA concentration, and the unacceptable assumption of similar pharmacokinetics for Gd(DTPA) and GdL 1 (43) .
Therefore, this quantitative pharmacokinetic study, which is beyond the scope of the present work, is not feasible in the present case.
One can safely conclude from the present study that the pharmacokinetic behaviour of both CAs is different, especially in the kidney medulla at later stages of excretion.
.
Conclusions
In this manuscript we describe the synthesis of the benzoylamide conjugate of were obtained by the inversion recovery method, and transverse relaxation rates (1/T 2 )
by the Carr-Purcell-Meiboom-Gill spin-echo technique. As an external reference, acidified water of pH 3.4 was used.
NMRD measurements
The measurements were performed by using a Stelar Spinmaster FFC NMR 
Relaxivity studies of pH dependence and Zn 2+ transmetallation
The transmetallation reaction of GdL 1 with Zn 2+ was studied by following the time dependent decrease of the water proton longitudinal relaxation rate, R 1 , of a phosphate-buffered saline solution (PBS, pH 7.1, 10 mM) containing 1.5 mM of GdL 1 after adding an equimolar amount of ZnCl 2 while the sample was vigorously stirred (53) . The water longitudinal relaxation rate was also measured as a function of time on the PBS buffered solution (pH 7.1, 10 mM) containing 2.5 mM GdL 1 (54) . The pH dependence of the relaxivity of the GdL 1 solution was also measured. A Bruker Minispec mq20 (20 MHz, 298 K) relaxometer was used for all measurements.
MRI experiments
In vivo MRI studies. The experimental protocols performed were approved by the appropriate institutional review committees and meet the guidelines of their responsible governmental agency. 
O NMR spectroscopy
From the measured 17 O NMR relaxation rates and angular frequencies of the paramagnetic solutions, 1/T 2 and , and of the acidified water reference, 1/T 2A and   , one can calculate the reduced relaxation rates and chemical shifts, 1/T 2r and  r , which may be written as in Equations (A1)-(A2), where, 1/T 2m is the relaxation rate of the bound water and  m is the chemical shift difference between bound and bulk water,  m is the mean residence time or the inverse of the water exchange rate k ex and P m is the mole fraction of the bound water. 
Previous studies have shown that outer sphere contributions to the 17 O relaxation rates are negligible. [3] In equation (A2) the chemical shift of the bound water molecule,  m , depends on the hyperfine interaction between the Gd III electron spin and the 17 O nucleus and is directly proportional to the scalar coupling constant,  A , as expressed in Equation (A3). The isotopic Landé g factor is equal to 2.0 for the Gd III , B represents the magnetic field, and k B is the Boltzmann constant.
The outer-sphere contribution to the chemical shift is assumed to be linearly related to Δω m by a constant C os [Equation (A4)]. [5] Δω os = C os Δω m (A4)
In the transverse relaxation, the scalar contribution, 1/T 2sc , is the most important [Equation (A9)]. 1/ s1 is the sum of the exchange rate constant and the electron spin relaxation rate. 
